Ablynx wins €2.1m grant from Flemish Agency for Innovation by Science and Technology

13-Aug-2014

To support development of nanobodies for ocular applications

Belgian biopharmaceutical company Ablynx has been awarded a €2.1m grant by the Flemish Agency for Innovation by Science and Technology (IWT) to help advance a novel approach to the treatment of diseases of the eye using some of the unique characteristics of nanobodies.

The grant is available over a period of three years and will allow the development and subsequent testing of nanobody leads in relevant pre-clinical disease models.

Sign up for your free email newsletter

\'Ophthalmology is an increasingly important area for many pharmaceutical companies as they seek to meet the demands of an ageing population,\' said Tony De Fougerolles, CSO of Ablynx.

Companies